These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37461921)

  • 21. Diagnosis of Autoimmune Blistering Diseases.
    Witte M; Zillikens D; Schmidt E
    Front Med (Lausanne); 2018; 5():296. PubMed ID: 30450358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis.
    Yang M; Wu H; Zhao M; Long H; Lu Q
    J Dermatolog Treat; 2022 May; 33(3):1356-1367. PubMed ID: 32799714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of autoimmune blistering diseases in pregnancy and the neonate.
    Krain RL; Chen KL; Werth VP
    G Ital Dermatol Venereol; 2019 Oct; 154(5):539-549. PubMed ID: 31195784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men.
    Behkar A; Garmaroudi G; Nasimi M; Yousefi S; Khosravi H; Kianfar N; Murrell DF; Daneshpazhooh M
    Int J Womens Dermatol; 2022 Mar; 8(1):e004. PubMed ID: 35620025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review.
    Edwards G; Diercks GFH; Seelen MAJ; Horvath B; van Doorn MBA; Damman J
    Front Immunol; 2019; 10():1477. PubMed ID: 31293600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimizing complications in autoimmune blistering diseases.
    Clay T; Pandya AG
    Dermatol Clin; 2011 Oct; 29(4):577-83. PubMed ID: 21925001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Analysis of BIOCHIP Mosaic-based Indirect Immunofluorescence with Direct Immunofluorescence in Diagnosis of Autoimmune Bullous Diseases: A Cross-Sectional Study.
    Arunprasath P; Rai R; Venkataswamy C
    Indian Dermatol Online J; 2021; 12(1):105-109. PubMed ID: 33768030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Direct Immunofluorescence in Diagnosis of Autoimmune Bullous Diseases: A Cross-Sectional Study.
    Arunprasath P; Rai R; Venkataswamy C
    Indian Dermatol Online J; 2020; 11(6):915-919. PubMed ID: 33344339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of autoimmune bullous diseases among children in Kuwait.
    Nanda A; Lazarevic V; Rajy JM; Almasry IM; AlSabah H; AlLafi A
    Pediatr Dermatol; 2021 Jan; 38(1):50-57. PubMed ID: 33043506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune bullous diseases in Austria.
    Laimer M; Pohla-Gubo G; Kraus L; Nischler E; Bauer JW; Ahlgrimm-Siess V; Hintner H
    Dermatol Clin; 2011 Oct; 29(4):691-8. PubMed ID: 21925021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of autoimmune blistering diseases on work productivity.
    Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of pemphigus and pemphigoid autoantibodies in the general population.
    Prüßmann W; Prüßmann J; Koga H; Recke A; Iwata H; Juhl D; Görg S; Henschler R; Hashimoto T; Schmidt E; Zillikens D; Ibrahim SM; Ludwig RJ
    Orphanet J Rare Dis; 2015 May; 10():63. PubMed ID: 25971981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric autoimmune blistering disorders - a five-year demographic profile and therapy experience.
    Mahajan R; Handa S; Kumar S; Chatterji D; Saikia UN; De D
    Int J Dermatol; 2022 Dec; 61(12):1511-1518. PubMed ID: 35894223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.
    Patel PM; Jones VA; Behnam CT; Di Zenzo G; Amber KT
    Antibodies (Basel); 2021 May; 10(2):. PubMed ID: 34067512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases.
    Oh DD; Zhao CY; Murrell DF
    J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):595-603. PubMed ID: 26434420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blistering diseases in the mature patient.
    Lakoš Jukić I; Jerković Gulin S; Marinović B
    Clin Dermatol; 2018; 36(2):231-238. PubMed ID: 29566927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alopecia in Autoimmune Blistering Diseases: A Systematic Review of Pathogenesis and Clinical Features of Disease.
    Xie D; Bilgic-Temel A; Abu Alrub N; Murrell DF
    Skin Appendage Disord; 2019 Aug; 5(5):263-275. PubMed ID: 31559249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of autoimmune blistering diseases in Spain.
    Suárez R; España A; Herrero-González JE; Iranzo P; Mascaró JM
    Dermatol Clin; 2011 Oct; 29(4):673-6. PubMed ID: 21925016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Regulatory Immune Cells and Molecules in Autoimmune Bullous Dermatoses.
    Cao T; Shao S; Fang H; Li B; Wang G
    Front Immunol; 2019; 10():1746. PubMed ID: 31428090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.